Literature DB >> 22815313

Acetylenic linkers in lead compounds: a study of the stability of the propargyl-linked antifolates.

Wangda Zhou1, Kishore Viswanathan, Dennis Hill, Amy C Anderson, Dennis L Wright.   

Abstract

Propargyl-linked antifolates that target dihydrofolate reductase are potent inhibitors of several species of pathogenic bacteria and fungi. This novel class of antifolates possesses a relatively uncommon acetylenic linker designed to span a narrow passage in the enzyme active site and join two larger functional domains. Because the use of alkyne functionality in drug molecules is limited, it was important to evaluate some key physicochemical properties of these molecules and specifically to assess the overall stability of the acetylene. Herein, we report studies on four compounds from our lead series that vary specifically in the environment of the alkyne. We show that the compounds are soluble, chemically stable in water, as well as simulated gastric and intestinal fluids with half-lives of approximately 30 min after incubation with mouse liver microsomes. Their primary in vitro route of metabolism involves oxidative transformations of pendant functionality with little direct alteration of the alkyne. Identification of several major metabolites indicated the formation of N-oxides; the rate of formation of these oxides was highly influenced by branching substitutions around the propargyl linker. On the basis of the lessons of these metabolic studies, a more advanced inhibitor was designed, synthesized, and shown to have increased (t(1/2) = 65 min) metabolic stability while maintaining potent enzyme inhibition.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22815313      PMCID: PMC3463820          DOI: 10.1124/dmd.112.046870

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

1.  Mass spectral metabonomics beyond elemental formula: chemical database querying by matching experimental with computational fragmentation spectra.

Authors:  Dennis W Hill; Tzipporah M Kertesz; Dan Fontaine; Robert Friedman; David F Grant
Journal:  Anal Chem       Date:  2008-06-12       Impact factor: 6.986

2.  In vitro biological activity and structural analysis of 2,4-diamino-5-(2'-arylpropargyl)pyrimidine inhibitors of Candida albicans.

Authors:  Janet L Paulsen; Jieying Liu; David B Bolstad; Adrienne E Smith; Nigel D Priestley; Dennis L Wright; Amy C Anderson
Journal:  Bioorg Med Chem       Date:  2009-06-17       Impact factor: 3.641

3.  Structure-guided development of efficacious antifungal agents targeting Candida glabrata dihydrofolate reductase.

Authors:  Jieying Liu; David B Bolstad; Adrienne E Smith; Nigel D Priestley; Dennis L Wright; Amy C Anderson
Journal:  Chem Biol       Date:  2008-09-22

4.  Highly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis.

Authors:  Phillip M Pelphrey; Veljko M Popov; Tammy M Joska; Jennifer M Beierlein; Erin S D Bolstad; Yale A Fillingham; Dennis L Wright; Amy C Anderson
Journal:  J Med Chem       Date:  2007-02-02       Impact factor: 7.446

5.  Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant.

Authors:  Jimmy Lindberg; Snaevar Sigurdsson; Seved Löwgren; Hans O Andersson; Christer Sahlberg; Rolf Noréen; Kerstin Fridborg; Hong Zhang; Torsten Unge
Journal:  Eur J Biochem       Date:  2002-03

6.  Structure-based approach to the development of potent and selective inhibitors of dihydrofolate reductase from cryptosporidium.

Authors:  David B Bolstad; Erin S D Bolstad; Kathleen M Frey; Dennis L Wright; Amy C Anderson
Journal:  J Med Chem       Date:  2008-10-04       Impact factor: 7.446

7.  Probing the active site of Candida glabrata dihydrofolate reductase with high resolution crystal structures and the synthesis of new inhibitors.

Authors:  Jieying Liu; David B Bolstad; Adrienne E Smith; Nigel D Priestley; Dennis L Wright; Amy C Anderson
Journal:  Chem Biol Drug Des       Date:  2009-01       Impact factor: 2.817

8.  Crystal structures of wild-type and mutant methicillin-resistant Staphylococcus aureus dihydrofolate reductase reveal an alternate conformation of NADPH that may be linked to trimethoprim resistance.

Authors:  Kathleen M Frey; Jieying Liu; Michael N Lombardo; David B Bolstad; Dennis L Wright; Amy C Anderson
Journal:  J Mol Biol       Date:  2009-02-26       Impact factor: 5.469

9.  Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase.

Authors:  Jennifer M Beierlein; Kathleen M Frey; David B Bolstad; Phillip M Pelphrey; Tammy M Joska; Adrienne E Smith; Nigel D Priestley; Dennis L Wright; Amy C Anderson
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

10.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

Authors:  Thomas O'Hare; William C Shakespeare; Xiaotian Zhu; Christopher A Eide; Victor M Rivera; Frank Wang; Lauren T Adrian; Tianjun Zhou; Wei-Sheng Huang; Qihong Xu; Chester A Metcalf; Jeffrey W Tyner; Marc M Loriaux; Amie S Corbin; Scott Wardwell; Yaoyu Ning; Jeffrey A Keats; Yihan Wang; Raji Sundaramoorthi; Mathew Thomas; Dong Zhou; Joseph Snodgrass; Lois Commodore; Tomi K Sawyer; David C Dalgarno; Michael W N Deininger; Brian J Druker; Tim Clackson
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743

View more
  8 in total

1.  Charged Nonclassical Antifolates with Activity Against Gram-Positive and Gram-Negative Pathogens.

Authors:  Eric Scocchera; Stephanie M Reeve; Santosh Keshipeddy; Michael N Lombardo; Behnoush Hajian; Adrienne E Sochia; Jeremy B Alverson; Nigel D Priestley; Amy C Anderson; Dennis L Wright
Journal:  ACS Med Chem Lett       Date:  2016-05-05       Impact factor: 4.345

2.  Elucidating features that drive the design of selective antifolates using crystal structures of human dihydrofolate reductase.

Authors:  Kristen M Lamb; Narendran G-Dayanandan; Dennis L Wright; Amy C Anderson
Journal:  Biochemistry       Date:  2013-10-03       Impact factor: 3.162

3.  Nonracemic Antifolates Stereoselectively Recruit Alternate Cofactors and Overcome Resistance in S. aureus.

Authors:  Santosh Keshipeddy; Stephanie M Reeve; Amy C Anderson; Dennis L Wright
Journal:  J Am Chem Soc       Date:  2015-07-08       Impact factor: 15.419

4.  Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.

Authors:  Marc Perez; Tahar Ayad; Philippe Maillos; Valérie Poughon; Jacques Fahy; Virginie Ratovelomanana-Vidal
Journal:  ACS Med Chem Lett       Date:  2016-02-02       Impact factor: 4.345

5.  Direct Substitution of Arylalkynyl Carbinols Provides Access to Diverse Terminal Acetylene Building Blocks.

Authors:  Narendran G-Dayanandan; Eric W Scocchera; Santosh Keshipeddy; Heather F Jones; Amy C Anderson; Dennis L Wright
Journal:  Org Lett       Date:  2016-12-13       Impact factor: 6.005

6.  Propargyl-linked antifolates are dual inhibitors of Candida albicans and Candida glabrata.

Authors:  Narendran G-Dayanandan; Janet L Paulsen; Kishore Viswanathan; Santosh Keshipeddy; Michael N Lombardo; Wangda Zhou; Kristen M Lamb; Adrienne E Sochia; Jeremy B Alverson; Nigel D Priestley; Dennis L Wright; Amy C Anderson
Journal:  J Med Chem       Date:  2014-03-06       Impact factor: 7.446

7.  Structure-Guided In Vitro to In Vivo Pharmacokinetic Optimization of Propargyl-Linked Antifolates.

Authors:  M N Lombardo; N G-Dayanandan; S Keshipeddy; W Zhou; D Si; S M Reeve; J Alverson; P Barney; L Walker; J Hoody; N D Priestley; R S Obach; D L Wright
Journal:  Drug Metab Dispos       Date:  2019-06-14       Impact factor: 3.922

Review 8.  Unique indolizidine alkaloid securinine is a promising scaffold for the development of neuroprotective and antitumor drugs.

Authors:  Sergey Klochkov; Margarita Neganova
Journal:  RSC Adv       Date:  2021-05-26       Impact factor: 4.036

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.